Targeting Tumour Endothelial Cells in Liver Cancer: The end of beginning

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-12-25 DOI:10.1016/j.jhep.2024.12.032

Xiaohang Long, Tsz Tung Kwong, Alfred Sze-Lok Cheng, Stephen Lam Chan

引用次数: 0

Abstract

Section snippets

Declaration of Competing Interest

SLC serves an advisory member for AstraZeneca, MSD, Eisai, Elevar, Roche, Ipsen, and Hengrui, received research funds from MSD, Eisai, Ipsen, SIRTEX, and Zailab, and honoraria from AstraZeneca, Eisai, Roche, Ipsen, and MSD.

Acknowledgements

This work is partially supported by the General Research Fund (14118424 and 14109122), the Li Ka Shing Foundation (CUHK_2021) and the CUHK Strategic Seed Funding for Collaborative Research Scheme (NL/SSFCRS2022/0672/22en).

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.